Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

BioNexus Gene Lab Corp

CIK 1737523 BGLC·Services · All EDGAR filings ↗

Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

BioNexus Gene Lab Corp disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure Substantial doubt about ability to continue as a going concern

As reflected in the accompanying consolidated financial statements, for the year ended December 31, 2025, the Company recorded a net loss of $2,984,607 and negative cash outflows from operating activities of $1,838,382 and as of December 31, 2025, the Company incurred an accumulated deficit of $6,427,227. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-04-29
Prior form
10-K/A
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.
Late filing elevated Filing comparison

BioNexus Gene Lab Corp told the SEC it could not file its annual report on time

Evidence
Days past due date
0
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.